GSK Keeps Oncology 2.0 Growth Plans On Track

 
• By Mandy Jackson

Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality. 

Cancer Cell self destructing cancer cure treatment T-cell lymphocyte killing tumors 3D render
GSK's strategy includes immuno-oncology, synthetic lethality, cell and gene therapy, and epigenetics • Source: Shutterstock

More from Anticancer

More from Therapy Areas